Notably, the recommendations stratified mutated NPM1 and mutated FLT3-ITD AML (in the absence of a diagnostic or prognostic karyotype) as favorable or intermediate risk based on the FLT3-ITD AR < 0.5 or ≥0.5 [20]. This evidence concerns the gene FLT3 and acute myeloid leukemia.